Midatech initiates Phase 1 trial of a new hormonal cancer therapy
Category: #health  By Mateen Dalal  Date: 2019-10-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Midatech initiates Phase 1 trial of a new hormonal cancer therapy

Cancer treatment is one of the biggest challenges for the 21st century. There have been many advancements in the field of cancer treatment over the past few years. Clinical trial indeed plays a pivotal role in discovering new drugs, especially for treating serious diseases such as cancer. Numerous organizations across the world are putting in their best efforts to treat cancer effectively.

Midatech Pharma PLC is one such pharmaceutical research and development company that has reportedly started Phase 1 study of MTD201 for patients who are suffering from hormonal-based cancers such as neuroendocrine tumors (NET) and acromegaly.

According to reports, the first batch of healthy volunteers, 14 subjects out of 28, recently attained one dose of Sandostatin 100 microgram/1 ml solution followed by a 30mg injection of MTD201. Another 14 subjects will undergo the same procedures this week to complete the dosing phase of the clinical trial.

Sources cite that after completion of the dosing period, all subjects will undergo a 63-day sampling and observation period. Topline results are expected by the end of the last quarter of 2019 or early in the first quarter of 2020.

For a record, Midatech Pharma is working towards developing therapies using three novel delivery mechanisms as Q-Sphera , MidaCore, MidaSolve. These technologies are focused on enhancing the delivery and distribution of medicines in the body and are useful in exerting their actions in an effective, precise and safe manner.

MTD201 uses Q-Sphera, a polymer microsphere innovation that is used to control and prolong the release of therapeutics over a long period -from weeks to months. Midatech is also working with its clinical trial of MTX110 for patients who are suffering from brain cancer.

About the company

Midatech is a research and development pharmaceutical company that is focused on extending and enhancing the lives of patients who are suffering from rare and serious cancers. The company has created niche in this space by applying and developing novel drug delivery technologies to enhance existing or develop new therapies for serious diseases.

Source Credit - https://www.proactiveinvestors.co.uk/companies/news/904348/midatech-pharma-starts-phase-1-trial-of-hormonal-cancer-treatment-904348.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...